Journal
DRUGS OF TODAY
Volume 51, Issue 9, Pages 537-548Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2015.51.9.2386730
Keywords
Filgrastim; Acute radiation syndrome; PEG-G-CSF; t-metHuG-CSF
Categories
Ask authors/readers for more resources
The U.S. Food and Drug Administration (FDA) recently approved Neupogen (R) (filgrastim) for the treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. It is the first medical countermeasure currently approved by the FDA for this indication under the criteria of the FDA animal rule. This article summarizes the consequences of high-dose radiation exposure, a description of the hematopoietic acute radiation syndrome (H-ARS), the use of hematopoietic growth factors in radiation accident victims and current available treatments for H-ARS with an emphasis on the use of Neupogen in this scenario.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available